ArticleInfectious diseases & immunity2025
Impact on clinical biomarkers, immune recovery, and HIV reservoir dynamics of switching to EVG/c/FTC/TAF versus maintaining a non-INSTI-based regimen in virologically suppressed individuals.
Article in Infectious diseases & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Integrase Strand Transfer Inhibitors (INSTIs) have emerged as the preferred first-line antiretroviral therapy (ART) regimen globally, primarily due to their superior efficacy and favorable safety profile. However, in China, the high cost of INSTIs and their later market introduction have resulted in relatively limited reporting on INSTI-based regimens. Specifically, there is a lack of comprehensive data regarding side effects, immunological outcomes, and virological responses among the Chinese population living with human immunodeficiency virus (HIV). Against this backdrop, this cohort study aims to evaluate the changes in T-cells, laboratory parameters, viral decay, and CD8 Methods: From December 2022 to May 2023, 59 adults (aged 18-60 years), all of whom had received more than three years of ART and achieved sustained virological suppression (plasma HIV RNA <200 copies/mL for ≥6 months), were enrolled in this study at the Fifth Medical Center of Chinese PLA General Hospital. The participants were divided into two groups according to whether they received elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (EVG/c/FTC/TAF)-that is, whether they switched to EVG/c/FTC/TAF (the INSTI group, Results: At week 24, the INSTI group showed a significant increase in the CD4 Conclusion: The EVG/c/FTC/TAF regimen significantly improves immune recovery, enhances the CD8
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.